Dare Bioscience Net Income
| DARE Stock | USD 1.71 0.00 0.00% |
As of the 16th of February 2026, Dare Bioscience shows the Standard Deviation of 4.19, mean deviation of 2.98, and Variance of 17.55. Dare Bioscience technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Dare Bioscience information ratio, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Dare Bioscience is priced favorably, providing market reflects its regular price of 1.71 per share. Please also check Dare Bioscience jensen alpha, which is currently at (0.1) to verify the company can sustain itself at a future point.
Dare Bioscience Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 4.8688 | Revenue | Earnings Share (1.83) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -4.7 M | -4.9 M | |
| Net Loss | -4.7 M | -4.9 M | |
| Net Loss | -27.9 M | -29.2 M | |
| Net Loss | (0.43) | (0.45) | |
| Net Income Per E B T | 0.93 | 0.82 |
Dare | Net Income | Build AI portfolio with Dare Stock |
Analyzing Dare Bioscience's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Dare Bioscience's current valuation and future prospects.
Latest Dare Bioscience's Net Income Growth Pattern
Below is the plot of the Net Income of Dare Bioscience over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Dare Bioscience financial statement analysis. It represents the amount of money remaining after all of Dare Bioscience operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Dare Bioscience's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dare Bioscience's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (4.05 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Dare Net Income Regression Statistics
| Arithmetic Mean | 4,369,612 | |
| Geometric Mean | 20,217,229 | |
| Coefficient Of Variation | 2,388 | |
| Mean Deviation | 47,345,018 | |
| Median | (19,563,000) | |
| Standard Deviation | 104,343,276 | |
| Sample Variance | 10887.5T | |
| Range | 446.4M | |
| R-Value | 0.24 | |
| Mean Square Error | 10951.3T | |
| R-Squared | 0.06 | |
| Significance | 0.36 | |
| Slope | 4,933,568 | |
| Total Sum of Squares | 174200.3T |
Dare Net Income History
Other Fundumenentals of Dare Bioscience
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Dare Bioscience Net Income component correlations
Dare Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Dare Bioscience is extremely important. It helps to project a fair market value of Dare Stock properly, considering its historical fundamentals such as Net Income. Since Dare Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dare Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dare Bioscience's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could Dare diversify its offerings? Factors like these will boost the valuation of Dare Bioscience. Projected growth potential of Dare fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dare Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.83) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
Understanding Dare Bioscience requires distinguishing between market price and book value, where the latter reflects Dare's accounting equity. The concept of intrinsic value - what Dare Bioscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Dare Bioscience's price substantially above or below its fundamental value.
It's important to distinguish between Dare Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dare Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Dare Bioscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Dare Bioscience 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Dare Bioscience's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Dare Bioscience.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Dare Bioscience on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Dare Bioscience or generate 0.0% return on investment in Dare Bioscience over 90 days. Dare Bioscience is related to or competes with FibroBiologics Common, Citius Pharmaceuticals, Ainos, Aspire BioPharma, Aditxt, Palisade Bio, and Adlai Nortye. Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing ... More
Dare Bioscience Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Dare Bioscience's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Dare Bioscience upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 26.52 | |||
| Value At Risk | (6.98) | |||
| Potential Upside | 6.55 |
Dare Bioscience Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dare Bioscience's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Dare Bioscience's standard deviation. In reality, there are many statistical measures that can use Dare Bioscience historical prices to predict the future Dare Bioscience's volatility.| Risk Adjusted Performance | 0.0045 | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | (0.03) |
Dare Bioscience February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0045 | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 2.98 | |||
| Coefficient Of Variation | (22,271) | |||
| Standard Deviation | 4.19 | |||
| Variance | 17.55 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 26.52 | |||
| Value At Risk | (6.98) | |||
| Potential Upside | 6.55 | |||
| Skewness | 1.03 | |||
| Kurtosis | 4.57 |
Dare Bioscience Backtested Returns
At this point, Dare Bioscience is unstable. Dare Bioscience secures Sharpe Ratio (or Efficiency) of close to zero, which denotes the company had a close to zero % return per unit of risk over the last 3 months. We have found twenty-one technical indicators for Dare Bioscience, which you can use to evaluate the volatility of the firm. Please confirm Dare Bioscience's Standard Deviation of 4.19, mean deviation of 2.98, and Variance of 17.55 to check if the risk estimate we provide is consistent with the expected return of 0.0141%. The firm shows a Beta (market volatility) of 1.15, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Dare Bioscience will likely underperform. Dare Bioscience right now shows a risk of 4.17%. Please confirm Dare Bioscience kurtosis, and the relationship between the treynor ratio and day median price , to decide if Dare Bioscience will be following its price patterns.
Auto-correlation | -0.6 |
Good reverse predictability
Dare Bioscience has good reverse predictability. Overlapping area represents the amount of predictability between Dare Bioscience time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Dare Bioscience price movement. The serial correlation of -0.6 indicates that roughly 60.0% of current Dare Bioscience price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.6 | |
| Spearman Rank Test | -0.82 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Dare Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Dare Bioscience reported net income of (4.05 Million). This is 101.19% lower than that of the Health Care Equipment & Supplies sector and 105.79% lower than that of the Health Care industry. The net income for all United States stocks is 100.71% higher than that of the company.
Dare Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dare Bioscience's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dare Bioscience could also be used in its relative valuation, which is a method of valuing Dare Bioscience by comparing valuation metrics of similar companies.Dare Bioscience is currently under evaluation in net income category among its peers.
Dare Bioscience Institutional Holders
Institutional Holdings refers to the ownership stake in Dare Bioscience that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Dare Bioscience's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dare Bioscience's value.| Shares | Global Retirement Partners, Llc. | 2025-06-30 | 4.4 K | Hanson Mcclain Inc | 2025-06-30 | 1.7 K | Tower Research Capital Llc | 2025-06-30 | 1.4 K | Ifs Advisors, Llc | 2025-06-30 | 950 | Sbi Securities Co Ltd | 2025-06-30 | 575 | Bank Of America Corp | 2025-06-30 | 99.0 | Caldwell Sutter Capital Inc | 2025-06-30 | 17.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 7.0 | Cornerstone Planning Group Llc | 2025-06-30 | 2.0 | Vanguard Group Inc | 2025-06-30 | 328.3 K | Amh Equity Ltd | 2025-06-30 | 193.6 K |
Dare Fundamentals
| Return On Equity | -25.43 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 4.15 M | ||||
| Shares Outstanding | 13.48 M | ||||
| Shares Owned By Insiders | 8.73 % | ||||
| Shares Owned By Institutions | 8.01 % | ||||
| Number Of Shares Shorted | 310.4 K | ||||
| Price To Earning | (43.44) X | ||||
| Price To Book | 8.50 X | ||||
| Price To Sales | 751.51 X | ||||
| Revenue | 9.78 K | ||||
| Gross Profit | (14.35 M) | ||||
| EBITDA | (23.41 M) | ||||
| Net Income | (4.05 M) | ||||
| Cash And Equivalents | 40.39 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 1.3 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 2.17 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | 5.39 M | ||||
| Short Ratio | 3.87 X | ||||
| Earnings Per Share | (1.83) X | ||||
| Target Price | 10.75 | ||||
| Number Of Employees | 21 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 22.92 M | ||||
| Total Asset | 22.1 M | ||||
| Retained Earnings | (175.29 M) | ||||
| Working Capital | (3.16 M) | ||||
| Current Asset | 7.58 M | ||||
| Current Liabilities | 17.82 M | ||||
| Net Asset | 22.1 M |
About Dare Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dare Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dare Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dare Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Dare Bioscience is a strong investment it is important to analyze Dare Bioscience's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Dare Bioscience's future performance. For an informed investment choice regarding Dare Stock, refer to the following important reports:Check out For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Health Care Equipment & Supplies sector continue expanding? Could Dare diversify its offerings? Factors like these will boost the valuation of Dare Bioscience. Projected growth potential of Dare fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dare Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.83) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
Understanding Dare Bioscience requires distinguishing between market price and book value, where the latter reflects Dare's accounting equity. The concept of intrinsic value - what Dare Bioscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Dare Bioscience's price substantially above or below its fundamental value.
It's important to distinguish between Dare Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dare Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Dare Bioscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.